SecBot SecBot
PRESS-RELEASE ·Filed Sep 1, 2026

BMRN

BioMarin
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The acquisition adds early-stage pipeline optionality but no near-term revenue or catalyst. Monitor Phase 1/2a data readouts for ALE1 and any future disclosure of deal economics. The separate Ascendis settlement (8-K filed Aug 31) provides a clearer near-term value driver via royalty stream on Yuviwel.

DirectionNeutral
Confidencemedium
Horizonmonths

BMN 440

● Neutral Named in this press release
Impact
Phase
Phase 1/2a
Time to market
At least 4-6 years, assuming successful Phase 1/2a data in 2027, followed by Phase 2b/3 trials and regulatory filing.
Next catalyst
None dated

What to watchThe next catalyst for BMN 440 is Phase 1/2a safety and pharmacodynamics data expected in 2027 (no specific month given). Positive data would validate the oral small-molecule approach in HPP and support advancement to later-stage trials, while any safety or efficacy signal issues would raise questions about the $275M Alesta acquisition. For now, the program is too early and too small relative to BioMarin's overall portfolio to be a standalone driver of the stock.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$64.84
T+0 close · Sep 1, 2026 · via day close
Latest settled
−7.46%
T+20 · $60.00 · next T+60 in 8d
Vs SPY
−7.78%
α at T+20
Latest observation
−9.73%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $64.84entry
  2. T+1 · 3mo ago +3.29%α +2.84% · $66.97
  3. T+5 · 2mo ago −0.66%α −0.74% · $64.41
  4. T+20 · 7w ago −7.46%α −7.78% · $60.00
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for hypophosphatasia (HPP), to its skeletal conditions portfolio. No financial terms were disclosed; the deal is a bolt-on pipeline addition for a $12.6B biotech with nine marketed products.

Key Facts

  • Acquisition of Alesta Therapeutics closed; Alesta becomes a wholly owned subsidiary of BioMarin.
  • Lead asset ALE1 is an oral small-molecule therapy for hypophosphatasia (HPP), a rare genetic bone disease.
  • ALE1 is currently in a Phase 1/2a trial assessing safety, tolerability, and PK/PD in healthy volunteers and adults with HPP.
  • No upfront payment, milestone, or royalty terms were disclosed in the press release.

Financial Impact

No financial terms disclosed; deal is immaterial relative to BioMarin's $12.6B market cap.

Risk Factors

  • ALE1 is early-stage (Phase 1/2a) with no guarantee of clinical or regulatory success.
  • Integration of a small private company may distract from BioMarin's core commercial portfolio.
  • No deal value disclosed limits ability to assess financial impact or ROI.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (33 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302865598

Track record

16 reports on BMRN

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
  2. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
  3. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
  5. Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
  6. Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
  7. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  9. Sep 1, 202610w ago Press Release Neutral 4/10 Viewing Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  10. Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026